Sermorelin
One of the safest and most studied growth hormone peptides, with the longest track record in clinical use. It was actually FDA-approved (as Geref) for children with growth hormone deficiency before being discontinued for business reasons, not safety concerns. Like CJC-1295, it tells your pituitary to release its own growth hormone naturally. Popular in anti-aging medicine as a gentle, well-understood option.
Sermorelin is a 29-amino-acid synthetic peptide analog of the first 29 amino acids of natural growth hormone-releasing hormone (GHRH). It was previously FDA-approved as Geref for diagnosing growth hormone deficiency in children, making it one of the few GH peptides with a formal regulatory history. While the commercial product was discontinued for business reasons rather than safety concerns, sermorelin remains widely used in compounding pharmacy protocols.
Sermorelin stimulates the pituitary gland to produce and release growth hormone through the natural GHRH receptor pathway. Because it works through the body's own feedback mechanisms, it maintains the normal pulsatile pattern of GH secretion and carries a lower risk of excessive GH levels compared to direct HGH administration. The pituitary's own negative feedback loop provides a natural safety ceiling.
Sermorelin is typically dosed at 200-300 mcg subcutaneously once daily before bed. It is often the entry-level GH peptide recommended for anti-aging protocols due to its established safety profile and gentle mechanism. Effects develop gradually over 3-6 months and include improved sleep quality, enhanced recovery, better skin elasticity, and gradual improvements in body composition.
Dosage
200-300 mcg subcutaneous once daily before bed
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Subcutaneous injection (typically before bedtime)
Get Research-Grade Sermorelin
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
GH Release
Stimulates physiological pulsatile GH release within natural feedback loops.
Anti-Aging
Supports body composition, sleep, and recovery through natural GH optimization.
Recovery
Enhanced sleep quality and GH pulses support tissue repair and exercise recovery.
Body Composition
Gradual improvements in lean mass and fat reduction through natural GH optimization.
Mechanism of Action
Sermorelin is a synthetic peptide consisting of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-44). These 29 residues contain the full biological activity domain required for GHRH receptor activation — the remaining 15 amino acids of native GHRH are not necessary for receptor binding or signal transduction.
Sermorelin binds to the GHRH receptor on anterior pituitary somatotrophs, activating the Gs/adenylyl cyclase pathway to increase intracellular cAMP. This triggers PKA-mediated phosphorylation of CREB and stimulates both GH gene transcription and the release of pre-formed GH vesicles. Because sermorelin works through the body's own regulatory system, GH release occurs in a physiological pulsatile pattern governed by the interplay between GHRH stimulation and somatostatin inhibition — the hypothalamic-pituitary feedback loop remains intact.
This preservation of feedback regulation is sermorelin's primary safety advantage over exogenous GH administration. The pituitary gland can only release as much GH as it has synthesized, providing a natural ceiling effect that prevents supraphysiological GH levels. Somatostatin feedback still functions normally, ensuring appropriate pulse spacing. Additionally, because the pituitary itself is being stimulated rather than bypassed, sermorelin may help maintain or even restore pituitary somatotroph function over time. It was the first GHRH analogue to receive FDA approval (as Geref), specifically for evaluating pituitary GH reserve and treating pediatric GH deficiency, giving it one of the longest clinical track records among GH-stimulating peptides.
Regulatory Status
Previously FDA approved (Geref) for pediatric GH deficiency. Withdrawn 2008 for commercial reasons. Available through compounding pharmacies.
Risks & Safety
Common
injection site redness and swelling, headache, facial flushing, brief dizziness.
Serious
theoretical risk of promoting existing tumours.
Rare
allergic reactions, hives at injection site.
Compare Sermorelin With
Research Papers
24Published: December 31, 2025
AI Summary
Peptides such as GHK-Cu support wound healing, while growth hormone secretagogues like sermorelin promote muscle repair via IGF-1. The review outlines their mechanisms and the need for more clinical trials in orthopedics.
Published: January 14, 2026
AI Summary
A nano-LC mass spectrometry method was developed to detect GHRH and analogs like sermorelin in urine for anti-doping testing. The method met WADA requirements for sensitivity.
Published: October 8, 2025
AI Summary
GHRH antagonists triggered autophagy in cancer cells that express GHRH receptors. The finding may help explain their anti-cancer effects.
Published: March 31, 2025
AI Summary
GHRH antagonists made non-small cell lung cancer cells more sensitive to radiation. Combining them with radiotherapy may improve treatment outcomes.
Published: October 17, 2024
AI Summary
The GHRH receptor antagonist MIA-690 plus gefitinib worked better than either alone against castration-resistant prostate cancer in cells and mice. The combination blocked survival pathways.
Published: June 16, 2025
AI Summary
GHRH antagonists may offer a new option for acute myeloid leukemia, especially when combined with chemotherapy. The review summarizes preclinical evidence for MIA-602.
Published: April 7, 2024
AI Summary
The GHRH antagonist MIA-602 reduced viability of doxorubicin-resistant AML cell lines and slowed tumor growth in mice. It may help overcome drug resistance.
Published: January 12, 2024
AI Summary
A method was developed to detect peptidic drugs including sermorelin in urine for doping control. The approach met WADA performance requirements.
Published: November 27, 2023
AI Summary
The GHRH antagonist MIA-602 reduced lung and heart injury in a mouse model of COVID-19. Treatment improved breathing and dampened inflammation.
Published: November 30, 2023
AI Summary
A triple quadrupole UHPLC-MS/MS method was validated for detecting GHRHs including sermorelin in urine for anti-doping. Detection limits met WADA requirements.
Published: December 8, 2023
AI Summary
Sermorelin fragments were tested as internal standards for peptide analysis. GHRP-6 and Sermorelin (22-29) were stable and suitable for quantification.
Published: August 14, 2023
AI Summary
The GHRH antagonist MIA-602 reduced inflammation triggered by SARS-CoV-2 spike protein and bacterial LPS in immune cells. The finding suggests potential for treating COVID-19-related inflammation.
Published: June 19, 2023
AI Summary
The GHRH agonist MR-409 protected insulin-producing cells from streptozotocin-induced diabetes in mice. The agonist boosted survival pathways and preserved beta-cell mass.
Published: May 26, 2023
AI Summary
A capillary electrophoresis method was developed to separate and detect GHRH analogs including sermorelin in urine for anti-doping. Preconcentration improved sensitivity.
Published: August 21, 2022
AI Summary
A method was developed to detect peptidic drugs including sermorelin in blood for doping control. The approach met WADA requirements for initial testing.
Published: June 23, 2022
AI Summary
Exposure to GHRH transformed non-tumor prostate cells into tumor-forming cells in a xenograft model. The finding suggests GHRH may promote prostate cancer development.
Published: May 29, 2022
AI Summary
An ultrafiltration-based method detected GHRH analogs including sermorelin in urine at very low levels. The approach avoided antibody-based extraction.
Published: April 20, 2022
AI Summary
New GHRH antagonists showed stronger anti-cancer and anti-inflammatory effects than earlier versions. Some analogs outperformed MIA-602 in tumor models.
Published: January 12, 2022
AI Summary
A GHRH antagonist induced apoptosis in decidual stromal cells through ERK and JNK signaling. The finding may inform research on endometrial biology.
Published: November 6, 2021
AI Summary
In vitro metabolism of GHRH analogs including sermorelin was studied to improve anti-doping detection. Metabolites were identified and used to develop a sensitive detection method.
Published: December 29, 2021
AI Summary
The GHRH antagonist MIA-602 reduced anxiety and depression-like behavior in mice and had anti-inflammatory and antioxidant effects. The compound may warrant study for mood disorders and PTSD.
Published: September 14, 2021
AI Summary
The GHRH agonist MR-409 reduced oxidative stress and improved survival of insulin-secreting cells under ER stress. The mechanism needs further study.
Published: July 12, 2021
AI Summary
A GHRH agonist enhanced protection of retinal ganglion cells after optic nerve injury and worked together with macrophage activation. The agonist may have potential for glaucoma treatment.
Published: August 26, 2021
AI Summary
The GHRH antagonist MIA-690 increased food intake and body weight in mice by affecting appetite-related brain signals. The agonist MR-409 had no such effect.
Frequently Asked Questions
What is Sermorelin?
One of the safest and most studied growth hormone peptides, with the longest track record in clinical use. It was actually FDA-approved (as Geref) for children with growth hormone deficiency before being discontinued for business reasons, not safety concerns. Like CJC-1295, it tells your pituitary to release its own growth hormone naturally. Popular in anti-aging medicine as a gentle, well-understood option.
What is Sermorelin used for?
One of the safest and most studied growth hormone peptides, with the longest track record in clinical use. It was actually FDA-approved (as Geref) for children with growth hormone deficiency before being discontinued for business reasons, not safety concerns. Like CJC-1295, it tells your pituitary to release its own growth hormone naturally. Popular in anti-aging medicine as a gentle, well-understood option.
What is the dosage for Sermorelin?
Standard: 200-300 mcg subcutaneous once daily before bed. Often cycled 5 days on, 2 days off. Treatment courses of 3-6 months. Can be combined with Ipamorelin for enhanced GH release.
What are the side effects of Sermorelin?
Common: injection site redness and swelling, headache, facial flushing, brief dizziness. Serious: theoretical risk of promoting existing tumours. Rare: allergic reactions, hives at injection site.
How does Sermorelin work?
Sermorelin is a synthetic peptide consisting of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-44). These 29 residues contain the full biological activity domain required for GHRH receptor activation — the remaining 15 amino acids of native GHRH are not necessary for receptor binding or signal transduction. Sermorelin binds to the GHRH receptor on anterior pituitary somatotrophs, activating the Gs/adenylyl cyclase pathway to increase intracellular cAMP. This triggers PKA-mediated phosphorylation of CREB and stimulates both GH gene transcription and the release of pre-formed GH vesicles. Because sermorelin works through the body's own regulatory system, GH release occurs in a physiological pulsatile pattern governed by the interplay between GHRH stimulation and somatostatin inhibition — the hypothalamic-pituitary feedback loop remains intact. This preservation of feedback regulation is sermorelin's primary safety advantage over exogenous GH administration. The pituitary gland can only release as much GH as it has synthesized, providing a natural ceiling effect that prevents supraphysiological GH levels. Somatostatin feedback still functions normally, ensuring appropriate pulse spacing. Additionally, because the pituitary itself is being stimulated rather than bypassed, sermorelin may help maintain or even restore pituitary somatotroph function over time. It was the first GHRH analogue to receive FDA approval (as Geref), specifically for evaluating pituitary GH reserve and treating pediatric GH deficiency, giving it one of the longest clinical track records among GH-stimulating peptides.
How is Sermorelin administered?
Sermorelin is administered via subcutaneous injection (typically before bedtime).
What is the half-life of Sermorelin?
The half-life of Sermorelin is 10-20 minutes.
Is Sermorelin legal?
Previously FDA approved (Geref) for pediatric GH deficiency. Withdrawn 2008 for commercial reasons. Available through compounding pharmacies.
Related Peptides
ACE-031
An experimental drug that acts as a 'decoy' to intercept myostatin and other muscle-limiting signals before they reach your muscles. It produced rapid muscle gains in clinical trials without any exercise. However, development was halted because it also accidentally blocked signals needed to maintain healthy blood vessels, causing nosebleeds and visible broken blood vessels. A powerful proof-of-concept that myostatin blocking works, but too dangerous in its current form.
AEDG Peptide
A tetrapeptide (Ala-Glu-Asp-Gly) identical to Epithalon's core active sequence — effectively the same compound. Studied for telomerase activation and pineal gland regulation, promoting melatonin production and potentially slowing cellular aging through telomere maintenance. Part of the Khavinson bioregulator peptide family developed in St. Petersburg.
AICAR
A natural compound that activates your cells' energy sensor — the same pathway that turns on during exercise. Mimics the metabolic effects of endurance exercise at the cellular level, helping with fat burning, glucose uptake, and building more mitochondria. Banned by WADA as a metabolic modulator after detection in professional cycling.
BPC-157
A healing compound made from a protein found in stomach fluid. It's the most studied peptide for tissue repair, with research showing it helps heal tendons, ligaments, muscles, the gut, and other organs. It's stable enough to survive stomach acid, so you can take it either by injection under the skin or by mouth.